8-K: CareDx Q2 2026 Results: Revenue Surges 52%, Guidance Raised

CareDx reported a 52% year-over-year revenue increase to $132 million for Q2 2026, driven by strong Testing Services growth, and raised its full-year revenue and AEBITDA guidance.

Summary

• CareDx announced its second quarter 2026 financial results, reporting total revenue of $132 million, a 52% increase compared to the same period in 2025.
• Testing Services revenue grew by 61% year-over-year to $100 million, with testing volume increasing by 17% to approximately 58,000.
• Patient and Digital Solutions revenue increased by 50% to $19 million, and Lab Product revenue grew by 8% to $13 million.
• The company reported GAAP net income of $111 million, which includes a $113 million gain from the sale of its Lab Products business.
• Adjusted EBITDA was $25 million, a significant increase from $5 million in Q2 2025.
• CareDx raised its full-year 2026 revenue guidance to a range of $490 million to $500 million and its Adjusted EBITDA guidance to $66 million to $78 million.
• The company completed the divestiture of its Lab Products business and the acquisition of Naveris, Inc.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability, and raised forward-looking guidance, indicating robust business performance and strategic execution.

Positives

• Revenue increased by 52% year-over-year to $132 million in Q2 2026.
• Testing Services revenue saw a substantial 61% year-over-year increase to $100 million.
• Testing Services volume grew by 17% year-over-year.
• Patient and Digital Solutions revenue increased by 50% year-over-year.
• Adjusted EBITDA significantly improved to $25 million from $5 million in Q2 2025.
• Full-year 2026 revenue guidance was raised to $490 million $500 million.
• Full-year 2026 Adjusted EBITDA guidance was raised to $66 million $78 million.
• Cash flow from operations was $31 million.

Negatives

• Lab Product revenue, though growing 8%, will no longer be included in future periods due to its divestiture.
• While GAAP net income was high, it was significantly boosted by a one-time gain from the sale of the Lab Products business.

Risks

• Forward-looking statements are subject to numerous risks and uncertainties, including general economic and market factors, and global economic and marketplace uncertainties.
• The company disclaims any obligation to update forward-looking statements.
• The acquisition of Naveris, Inc. is a strategic move that will require successful integration and may present its own set of risks.
• Continued reliance on testing services revenue growth and adoption of molecular surveillance testing.

Future Outlook

CareDx raised its full-year 2026 revenue guidance to a range of $490 million to $500 million and its Adjusted EBITDA guidance to a range of $66 million to $78 million, reflecting confidence in continued growth and operational efficiency.

Management Comments

• "We have transformed CareDx into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us for continued profitable growth," said John Hanna, President and Chief Executive Officer of CareDx.
• "Our performance reflects that our strategy is working, and we look forward to building on our momentum as we integrate NavDx and launch into cell therapy."

Industry Context

StockSavvy.ai notes that CareDx's strong Q2 performance, particularly in testing services, aligns with the broader trend of increasing adoption of precision medicine and molecular diagnostics in transplant care and oncology. The acquisition of Naveris strengthens its position in cell therapy, a rapidly growing segment.

Comparison to Industry Standards

• The 52% year-over-year revenue growth for CareDx in Q2 2026 significantly outpaces the typical growth rates seen in the broader diagnostics industry, which often range from single digits to low double digits.
• The increase in Adjusted EBITDA to $25 million demonstrates improved operational leverage, a key metric for profitability that many companies in the diagnostics sector strive to achieve.
• The company's focus on transplant diagnostics, with products like AlloSure and AlloMap, addresses a specialized but critical area within healthcare, where advancements in molecular testing are driving better patient outcomes and potentially higher revenue per test compared to general diagnostics.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, profitability, and raised guidance, potentially leading to stock price appreciation.
• Employees: Positive impact from company growth and successful strategic initiatives, potentially leading to job security and opportunities.
• Customers (Transplant Programs, Hospitals): Continued access to critical diagnostic tools like AlloSure and AlloMap, supported by CMS coverage.
• Suppliers: Potential for increased business volume due to company growth.

Next Steps

• Integrate the acquired Naveris business.
• Continue to build momentum in cell therapy.
• Further develop and expand the AlloHeme pipeline program towards CLIA readiness.
• Continue to publish data supporting pipeline programs like HistoMap Kidney and NavDx.
• Leverage new CMS Medicare coverage policy for AlloSure and AlloMap.

Key Dates

Recommendation

The company demonstrated exceptional revenue growth, significantly improved profitability, and raised its full-year guidance, indicating strong execution and positive future prospects. The strategic divestiture and acquisition further position the company for specialized growth.

Keywords

precision medicine diagnostics, transplant diagnostics, specialty oncology, cell therapy, AlloSure, AlloMap, molecular testing, revenue growth